INTRODUCTION
============

Chronic obstructive pulmonary disease (COPD) is characterized by persistent and usually progressive airflow restriction [@b1-cln_73p1]. COPD may limit activity, compromise quality of life, and result in disability. As such, this disorder presents a major, incurable population health burden [@b2-cln_73p1]. In addition, COPD patients may suffer from additional systemic manifestations of the disorder. Comorbid medical conditions further contribute to disease severity, functional impairment, reduced quality of life, and poor clinical outcomes. Cardiovascular diseases (CVDs), including ischemic heart disease, atrial fibrillation, and heart failure, and cerebrovascular diseases are the most prevalent and fatal comorbidities of COPD [@b3-cln_73p1].

While the coexistence of COPD and CVD is well established, whether COPD increases the individual's risk for all types of CVD has not been confirmed. Shared risk factors, persistent inflammation, and vulnerability to infection have been proposed as mechanisms by which COPD and CVD might be linked [@b4-cln_73p1]. While there is evidence suggesting that COPD increases the risk of heart disease [@b4-cln_73p1],[@b5-cln_73p1], studies conducted to date on the risk of stroke among COPD patients have generated conflicting results. A recent review of the current evidence on stroke risk among COPD patients was limited by a dependence on cross-sectional data, which precluded a firm establishment of causality between COPD and stroke [@b4-cln_73p1].

To further investigate the relationship between COPD and stroke, we performed the present meta-analysis of longitudinal studies and evaluated incident stroke in COPD patient cohorts. The primary aim of this study was to clarify whether COPD patients are at increased risk of stroke. Secondary aims were to assess whether the association between COPD and stroke varies according to the type of stroke or the core adjusted variables, including socioeconomic status (SES). A systematic review of the literature on the association between stroke and COPD was undertaken in order to provide a comprehensive perspective on disease mechanisms in COPD and to identify potential strategies for stroke prevention among COPD patients.

METHODS
=======

Search strategy
---------------

Three databases (PubMed, EMBASE, and the Cochrane Library) were systematically searched from their inception to December 31, 2016. The following search terms were used to identify potential studies for inclusion: (COPD OR chronic obstructive airways disease OR chronic obstructive bronchial disease OR emphysema OR chronic bronchitis) and (stroke OR cerebrovascular disease OR cerebrovascular accident OR cerebral ischemia OR ischemic stroke OR transient ischemic accident OR hemorrhagic stroke). No search filters were applied. We also identified additional papers by reviewing the relevant articles listed in the references. This review followed the meta-analysis of observational studies in epidemiology (MOOSE) guidelines.

Study selection and inclusion criteria
--------------------------------------

Primary studies investigating stroke occurrence among COPD patients were eligible for inclusion. Additional eligibility criteria were that each study had to report the risk of developing stroke (e.g., not stroke-related mortality) and provide measures of association (hazard ratio (HR), incidence ratio (IR), or odds ratio (OR)) and precision (confidence interval (CI)). To investigate causality, we further narrowed the inclusion criteria to include only observational studies using a longitudinal study design. In the case of multiple publications using the same study population, only the most recent, largest, or most relevant publication was selected for inclusion.

Data extraction
---------------

Databases searches and data extraction were conducted by two independent investigators (YRK and YJL). Disagreements were resolved through consultation with a third author (ICH). The following information was extracted from each study: first author, year of publication, country, study setting, study design, measures of association with the corresponding 95% Cis, and core adjusted variables. Fully adjusted measures of association were extracted from the included studies. The Newcastle-Ottawa Scale, which is mainly based on potential confounding variables in the study populations, was used to assess methodological study quality.

Statistical analysis
--------------------

This investigation aimed to assess whether there is an increased risk of incident stroke among COPD patients compared to control subjects. Subgroup analyses were performed for stroke subtype (all types, ischemic stroke, or hemorrhagic stroke); study quality (low or high); and consideration of SES (unadjusted or adjusted). HRs (with 95% CIs) from the individual studies were pooled. Using well-established methods [@b6-cln_73p1] for calculating the variance of log HR from each study, we converted the 95% CIs to their natural logarithmic value by dividing the range of the CI by 3.92. We used Higgins *I^2^* (0-100%) to assess the heterogeneity across studies. When substantial heterogeneity (*I^2^*≥50%) was observed, we used the DerSimonian and Laird random-effects model as previously described [@b7-cln_73p1]. Random-effects models attempt to generalize findings beyond the included studies by assuming that the selected studies are random samples from a larger population [@b8-cln_73p1]. We also assessed publication bias using Begg's rank correlation test. Stata software (version 12.1, StataCorp, College Station, TX, USA) was used for all statistical analyses.

RESULTS
=======

[Figure 1](#f1-cln_73p1){ref-type="fig"} presents the flow diagram of the identification of relevant studies. From the 3,048 articles that were initially retrieved, 233 underwent abstract review, and 18 articles underwent full-text review. Ten articles were subsequently excluded for the following reasons: no relevant control group (n=4); no separate estimate of COPD association with stroke (n=4); or no estimates on exacerbated COPD (n=2). A total of eight studies were included in the final analysis.

Characteristics of the included studies are summarized in [Table 1](#t1-cln_73p1){ref-type="table"}. Most studies were conducted in Western countries (n=7) and investigated newly developed stroke (n=6). Only one study utilized a prospective cohort design. The core adjusted variables were metabolic comorbidities (hypertension, type 2 diabetes, and hyperlipidemia); prior CVD (ischemic heart disease and stroke); lifestyle (cigarette smoking, alcohol consumption, and obesity); and SES. Five recently published studies were rated as high-quality studies.

Overall, a significantly increased risk of stroke was observed among COPD patients (HR, 1.30; 95% CI, 1.18-1.43; *p*\<0.001; [Figure 2](#f2-cln_73p1){ref-type="fig"}). No single study unduly impacted the results. The association between COPD and stroke risk remained robust in subgroup analyses by stroke subtype, study quality, and adjustment for SES ([Table 2](#t2-cln_73p1){ref-type="table"}). Interestingly, high-quality studies and studies that adjusted for SES variables tended to have smaller effect sizes. Funnel plot asymmetry among studies was not observed (*p*=0.135; [Figure 3](#f3-cln_73p1){ref-type="fig"}).

DISCUSSION
==========

As comorbidities may substantially influence the severity and prognosis of COPD, studies exploring the associations between specific comorbidities and COPD are urgently needed. Stroke carries a significant risk of morbidity and mortality and is one of the most common causes of death and severe disability. Increased risk of stroke among COPD patients will increase the burden on their caregivers, whom are prone to adverse mental health when looking after COPD or stroke patients [@b9-cln_73p1],[@b10-cln_73p1]. Stroke may also contribute to pulmonary dysfunction due to impaired cough and/or weakness of respiratory muscles, resulting in an increased propensity for pneumonia [@b11-cln_73p1]. Accordingly, incident stroke in COPD can accelerate and further increase mortality risk. In our pooled analysis, COPD patients were found to have a 30% increased risk of developing stroke compared with non-COPD subjects. The observed association between COPD and stroke risk remained robust in subgroup analyses by stroke subtype and after adjustment for core variables. These results suggest that stroke risk should be closely monitored and controlled in patients with COPD.

Our subgroup analyses suggest that the increased stroke risk among COPD patients is not merely due to confounding by common risk factors, such as smoking, metabolic comorbidities, or SES. There is no doubt that cigarette smoking is associated with an increased risk of CVD, including stroke, and indeed, smoking has been shown to be associated with preclinical brain changes on magnetic resonance imaging [@b12-cln_73p1]. However, in prior studies of COPD and stroke, risk estimates were reduced by only approximately 10% after adjusting for smoking [@b13-cln_73p1],[@b14-cln_73p1]. In addition, cerebral small vessel disease has been shown to be significantly more prevalent among smokers with COPD than smokers without COPD [@b15-cln_73p1], suggesting an additional pathogenic effect of COPD beyond the harm from smoking itself. Socioeconomic inequalities may also potentially account for disparities among risk factors [@b16-cln_73p1]; however, in our analysis, SES did not critically impact the observed associations between COPD and increased stroke risk, which supports the existence of a COPD-specific effect.

Potential mechanisms by which COPD and stroke might be linked include increased systemic inflammation (for example, resulting in elevated interleukin-6 and C-reactive protein levels) and increased oxidative stress [@b17-cln_73p1]. COPD is a persistent airway inflammatory process and can potentially cause a continuous spillover of inflammatory mediators from the lungs into the blood stream [@b18-cln_73p1]. Many human studies have demonstrated increased serum levels of inflammatory and oxidative stress markers in COPD patients compared to controls [@b19-cln_73p1],[@b20-cln_73p1]. This dispersion of pro-inflammatory factors from the lungs may contribute to endothelial dysfunction and promote a pro-coagulative state, which may then lead to atherothrombosis, thereby providing a potential mechanistic link between COPD and the increased risk of cerebrovascular events [@b18-cln_73p1]. Furthermore, pro-inflammatory cytokines, including interleukin-6 and tumor necrosis factor alpha (TNF-α), were found to be elevated in depression [@b21-cln_73p1]. Depression is a common comorbidity of COPD [@b22-cln_73p1] and stroke [@b23-cln_73p1]. This observation further strengthens the neuro-immunological link among smoking, cardiovascular risk factors, COPD and stroke [@b24-cln_73p1]. Furthermore, the incidence rate of stroke has been found to be significantly increased following acute COPD exacerbations [@b25-cln_73p1],[@b26-cln_73p1]. Such exacerbations represent times of intense oxidative stress and increased systemic inflammation [@b27-cln_73p1]. However, to date, no clinical data have suggested that suppression of inflammation prevents or improves CVD outcomes. For example, statin use was not beneficial for COPD patients, and use of an inhaled corticosteroid was not found to affect cardiac mortality [@b28-cln_73p1],[@b29-cln_73p1].

Another mechanism by which COPD may specifically increase the risk of stroke is through hypoxemia. COPD patients, particularly those with more advanced disease, may experience hypoxemia, and subsequent hyperventilation contributes to vessel wall changes [@b30-cln_73p1]. Metabolic disturbances resulting from hyperventilation may also induce cardiac arrhythmias. Reduced lung function in COPD patients has been found to be inversely associated with incident atrial fibrillation, another condition that might predispose patients to stroke [@b31-cln_73p1]. COPD represents more than impaired lung function, but reduced lung capacity itself, regardless of the cause, has been associated with increased risk of atrial fibrillation [@b32-cln_73p1],[@b33-cln_73p1], stroke [@b34-cln_73p1],[@b35-cln_73p1] and CVD mortality [@b36-cln_73p1].

In the current study, although the majority of stroke events among COPD patients were of the ischemic type, the association between COPD and the risk of hemorrhagic stroke was also robust. Levels of plasminogen activator inhibitor-1 (PAI-1), a major inhibitor of fibrinolysis, were found to be higher in COPD patients and may contribute to thrombosis and ischemic stroke among these patients [@b37-cln_73p1]. Plasminogen activators were found to be beneficial for patients with mild stroke [@b38-cln_73p1]. However, additional study is required to evaluate the efficacy and safety of plasminogen activators as a treatment for stroke among COPD patients. Some risk factors are shared across all stroke subtypes, while others are differentially related [@b39-cln_73p1]. Aging and smoking are known to disrupt the blood-brain barrier [@b40-cln_73p1],[@b41-cln_73p1], which may contribute to the increased risk of hemorrhagic stroke among COPD patients. High blood pressure is also a major risk factor for hemorrhagic stroke [@b42-cln_73p1], and accumulation of blood within the brain may rapidly lead to damage due to mechanical injury and increased pressure [@b43-cln_73p1]. Prevalent use of anticoagulant therapy for arrhythmias [@b3-cln_73p1] in COPD patients may also partly explain the association between COPD and the increased risk of hemorrhagic stroke.

The present study has some limitations, mainly regarding study design, as it relied on data from studies using administrative healthcare databases. When using administrative healthcare data, there exists uncertainty regarding the diagnoses of COPD and stroke; healthcare databases usually do not contain records of lung function tests and brain imaging studies. Records from these sources also lack information on several important characteristics, including lifestyle factors such as smoking status, alcohol consumption, and physical and sedentary activity, thus preventing further stratified analyses. Variation among adjusted variables might partially account for the high heterogeneity found in the current meta-analysis. Another limitation of the included studies was that there was insufficient information on medication effects. COPD patients frequently use medications that may induce an acute CVD episode, including anticholinergic agents and sympathomimetic medications [@b44-cln_73p1],[@b45-cln_73p1]. COPD patients may also require treatment with macrolides and quinolone antibiotics, which are both associated with increased risk of adverse cardiovascular side effects [@b46-cln_73p1]. Finally, in this meta-analysis, there were not enough studies from non-Western countries, such as Asian studies. Further research is required to study the risk of stoke among Asian patients with COPD. At present, there are reports that Asian patients with COPD and stroke are more likely to report negative health and functional status [@b47-cln_73p1]. To further clarify the relationship between COPD and stroke risk, well-designed, prospective cohort studies with collaborating interventional trials are required. Further basic science studies are also required to explore whether targeting oxidative stress and lung and systemic inflammatory pathways may provide effective approaches for preventing vascular injury.

In conclusion, the results of this study suggest that COPD increases the risk of stroke, independent of other shared CVD risk factors. Current knowledge on the most effective approach for reducing stroke risk in COPD patients is still limited. For example, anticoagulant therapy is indicated only for COPD patients with atrial fibrillation [@b48-cln_73p1]. Primary care physicians should pay close attention to CVD risk, including stroke risk, from the time of COPD diagnosis, and where appropriate, they should work more closely with cardiologists and neurologists to enable optimal vascular care for patients with COPD.
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###### 

Characteristics of studies reporting the risk of incident stroke among COPD patients.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                   Country       Setting                              Design                Outcomes       Stroke risk (95% CI)                                            Adjusted variables other than age and sex                          NOS
  ------------------------------------ ------------- ------------------------------------ --------------------- -------------- --------------------------------------------------------------- ------------------------------------------------------------------ -----
  Söderholm, 2016 ([@b49-cln_73p1])    Sweden        103,419 COPD/103,419 without COPD    Nested case-control   First stroke   All: 1.24 (1.19-1.28)\                                          Metabolic comorbidities[c](#tfn4-cln_73p1){ref-type="table-fn"}\   8
                                                                                                                               IS: 1.20 (1.15-1.25)\                                           Prior CVD\                                                         
                                                                                                                               HS: 1.32 (1.20-1.45)[a](#tfn2-cln_73p1){ref-type="table-fn"}    Lifestyle (alcohol)\                                               
                                                                                                                                                                                               SES\                                                               
                                                                                                                                                                                               Others comorbidities[d](#tfn5-cln_73p1){ref-type="table-fn"}       

  Portegies, 2016 ([@b25-cln_73p1])    Netherlands   1,566 COPD/11,549 without COPD       Prospective cohort    First stroke   All: 1.07 (0.89-1.27)\                                          Metabolic comorbidities[c](#tfn4-cln_73p1){ref-type="table-fn"}\   9
                                                                                                                               IS: 1.10 (0.88-1.38)\                                           Prior CVD\                                                         
                                                                                                                               HS: 1.45 (0.86-2.45)                                            Lifestyle (BMI and smoking)\                                       
                                                                                                                                                                                               Others (hs-CRP and cIMT)                                           

  Lin, 2015 ([@b50-cln_73p1])          Taiwan        10,413 COPD/41,652 without COPD      Nested case-control   First stroke   All: 1.62 (1.49-1.77)\                                          Metabolic comorbidities[c](#tfn4-cln_73p1){ref-type="table-fn"}\   8
                                                                                                                               IS: 1.64 (1.49-1.82)[b](#tfn3-cln_73p1){ref-type="table-fn"}\   Prior CVD\                                                         
                                                                                                                               HS: 1.18 (0.89-1.57)[b](#tfn3-cln_73p1){ref-type="table-fn"}    Lifestyle (BMI, smoking, and alcohol)                              

  Schneider, 2010 ([@b13-cln_73p1])    UK            2,482 new COPD/6,116 without COPD    Nested case-control   First stroke   All: 1.13 (0.92-1.38)                                           Metabolic comorbidities[c](#tfn4-cln_73p1){ref-type="table-fn"}\   8
                                                                                                                                                                                               Lifestyle (BMI and smoking)                                        

  Feary, 2010 ([@b14-cln_73p1])        UK            26,915 COPD/1,136,898 without COPD   Nested case-control   First stroke   All: 1.39 (1.08-1.80)[a](#tfn2-cln_73p1){ref-type="table-fn"}   Metabolic comorbidities[c](#tfn4-cln_73p1){ref-type="table-fn"}\   8
                                                                                                                                                                                               Prior CVD\                                                         
                                                                                                                                                                                               Lifestyle (smoking)\                                               
                                                                                                                                                                                               SES                                                                

  Curkendall, 2006 ([@b31-cln_73p1])   Canada        11,493 COPD/22,986 without COPD      Nested case-control   Any stroke     All: 1.23 (0.68-2.22)                                           Metabolic comorbidities[c](#tfn4-cln_73p1){ref-type="table-fn"}\   7
                                                                                                                                                                                               Prior CVD                                                          

  Sidney, 2005 ([@b51-cln_73p1])       USA           36,931 COPD/44,137 without COPD      Nested case-control   First stroke   All: 1.39 (1.25-1.54)                                           Metabolic comorbidities[c](#tfn4-cln_73p1){ref-type="table-fn"}    7

  Huiart, 2005 ([@b52-cln_73p1])       Canada        5,648 new COPD/general population    Nested case-control   Any stroke     All: 1.27 (1.16-1.38)                                           None                                                               6
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

COPD, chronic obstructive pulmonary disease; CI, confidence interval; IS, ischemic stroke; HS, hemorrhagic stroke; CVD, cardiovascular disease; CRP, C-reactive protein; cIMT, carotid intima-media thickness; and NOS, Newcastle-Ottawa Scale.

Recalculated.

Not adjusted for lifestyle factors.

Hypertension, diabetes, and hyperlipidemia.

Including asthma, rheumatoid arthritis, lupus, and renal failure.

###### 

Risk of developing stroke among patients with COPD.

                                                                                                                  No. of studies   Summary HR (95% CI)   Heterogeneity, I^2^   Model
  --------------------------------------------------------------------------------------------------------------- ---------------- --------------------- --------------------- ----------------
  Stroke subtypes                                                                                                                                                              
   All stroke ([@b13-cln_73p1],[@b14-cln_73p1],[@b25-cln_73p1],[@b31-cln_73p1],[@b49-cln_73p1]-[@b52-cln_73p1])   8                1.30 (1.18-1.43)      82.4%                 Random-effects
   Ischemic stroke ([@b25-cln_73p1],[@b49-cln_73p1],[@b50-cln_73p1])                                              3                1.31 (1.03-1.66)      94.0%                 Random-effects
   Hemorrhagic stroke ([@b25-cln_73p1],[@b49-cln_73p1],[@b50-cln_73p1])                                           3                1.31 (1.20-1.43)      0%                    Fixed-effects
  Study quality                                                                                                                                                                
   Low ([@b31-cln_73p1],[@b51-cln_73p1],[@b52-cln_73p1])                                                          3                1.32 (1.23-1.41)      0%                    Fixed-effects
   High ([@b13-cln_73p1],[@b14-cln_73p1],[@b25-cln_73p1],[@b49-cln_73p1],[@b50-cln_73p1])                         5                1.28 (1.10-1.50)      89.3%                 Random-effects
  SES variables                                                                                                                                                                
   Unadjusted ([@b13-cln_73p1],[@b25-cln_73p1],[@b31-cln_73p1],[@b50-cln_73p1]-[@b52-cln_73p1])                   6                1.30 (1.14-1.49)      82.5%                 Random-effects
   Adjusted ([@b14-cln_73p1],[@b49-cln_73p1])                                                                     2                1.24 (1.20-1.29)      0%                    Fixed-effects

COPD, chronic obstructive pulmonary disease; SES, socioeconomic status; HR, hazard ratio; and CI, confidence interval.
